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ABSTRACT   
OBJECTIVE: To compare birth weight and weight gain in HIV-exposed, uninfected infants up to 
24 months old, who enrolled in the Malawian national HIV care clinic (HCC) programme either 
before or after Option B+ (OB+) was implemented.  
DESIGN, SETTING and PARTICIPANTS: HIV-exposed infants enrol in the HCC programme as 
soon as possible after birth and are followed up to at least 24 months old. This analysis includes 
HIV-exposed, uninfected (HEU) infants with recorded birth weight, date of birth, gender and at 
least one follow-up weight measurement from 21 health facilities in central and southern Malawi 
(January 2010 - December 2014). Weight-for-age z-scores (WAZ) were derived and compared 
by birth period using linear regression at birth and mixed effects models for postnatal weight 
gain up to 24 months old.   
RESULTS: Of 6,845 HEU infants included in this study, 88.5% were born after OB+. The 
proportion of infants exposed in-utero to combination antiretroviral therapy (ART) significantly 
increased after OB+ was implemented, and infants were exposed to ART for a longer time. 
There was no significant difference in WAZ at birth (p = 0.654) among HEU infants by birth 
period, but postnatal weight gain was faster among HEU infants born in the Option B+ period 
than infants born pre-Option B+.   
CONCLUSION: Birth weight was not affected by longer exposure to ART during pregnancy 
after OB+ was introduced, when weight gain in HEU infants was faster, possibly because their 
mothers were in better health. 
 
Keywords: 
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INTRODUCTION 
 
Scaling up prevention of mother-to-child transmission (PMTCT) interventions has drastically 
lowered the number of HIV-infected children worldwide. Without intervention, the likelihood of 
mother-to-child transmission (MTCT) of HIV ranges from 15% to 45%, but effective PMTCT 
interventions can reduce this risk to under 5% [1]. In Malawi, PMTCT coverage remained sub-
optimal until 2011, when the Ministry of Health (MoH) pioneered implementation of universal 
lifelong combination antiretroviral therapy (ART) for pregnant and breastfeeding women 
regardless of their CD4 cell count or clinical stage (“Option B+” (OB+)) [2]. As a consequence 
of the scale-up of OB+, ART coverage in pregnant and breastfeeding women has increased and 
MTCT risk of HIV declined [3] resulting in a growing number of HIV-exposed, uninfected 
(HEU) children. 
Although scaling up of PMTCT has greatly improved maternal health, there is concern that in-
utero exposure to antiretrovirals may negatively affect birth outcomes, growth and development 
of infants born to HIV-infected mothers [4–6]. Some studies reported that in-utero antiretroviral 
exposure is associated with low birth weight [6–8]; others found no such association [9–12]. 
Some studies found differences in weight gain [13–17] between HEU infants and healthy 
controls. A systematic review published in 2014 was inconclusive about the effect of in-utero 
HIV and antiretroviral exposure on postnatal weight gain of HIV-exposed infants [4].  
 
Although some studies have examined the association between in-utero ART exposure and 
adverse birth outcomes in the OB+ era [18,19], no study has investigated if OB+ affects the 
growth of HEU infants. We investigated the impact of OB+ on postnatal weight gain of 
Malawian HEU infants in the first 24 months of their lives under programmatic circumstances.  
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METHODS 
Study setting  
Malawi’s MoH provides integrated services for HIV-exposed infants in the national HIV care 
clinic (HCC) programme under Integrated HIV Management guidelines [20] as previously 
described [21]. Programme data suggest that most known HIV-exposed infants are enrolled and 
managed in this programme with regular clinic follow-up from 6 weeks after birth [20,22].  
 
Study design and inclusion criteria 
We included infants born to an HIV-infected woman, who enrolled in the HCC programme 
between January 2010 and December 2014 at any of the 21 large health facilities in central and 
southern Malawi that participated in our study to evaluate the implementation of OB+ 
(www.umoyoplus.org) (Figure 1).  The facilities included 13 district hospitals, two central 
hospitals, three faith based hospitals, and three large health centres. All infants who had a 
negative HIV test result were included. HIV-infected infants diagnosed positive at any point 
during follow-up and infants with unknown HIV status were excluded. We also excluded infants 
with missing birth date, birth weight or sex, and infants with no follow-up weight measurement. 
Infants were included in the analysis from enrolment until the last recorded follow-up visit. 
 
Data collection, preparation and management 
Registration and follow-up data for HIV-exposed infants enrolled in the HCC programme are 
recorded on standardized paper-based treatment cards stored at health facilities. At each visit, 
trained health care workers measure infant’s weight with a mechanical scale that is calibrated 
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daily [23]. Routinely collected data were digitized from the treatment cards, followed by double 
data entry and cleaning. Records were de-duplicated using probabilistic linkage [21].  
 
Definitions and outcomes 
Programmatic outcomes at the end of follow-up were defined as under follow-up, died, 
discharged uninfected, transferred out to another health facility, or lost to follow-up (LTFU). 
LTFU was defined as missing a clinic appointment for more than 60 days and not returning to 
care. ART was defined as a combination of at least three antiretroviral drugs. Before OB+, 
women eligible for ART received a combination of stavudine, lamivudine and nevirapine. 
Women not eligible for ART received zidovudine monotherapy during pregnancy followed by 
zidovudine + lamivudine dual therapy or single-dose nevirapine during labour. During OB+, all 
women received a combination of tenofovir, lamivudine and efavirenz.  
 
We defined birth period as pre-Option B+ (pre-OB+) or Option B+ (OB+) using the date each 
facility switched to OB+. Infants born within a few months of the health facility’s switch to OB+ 
were classified into the OB+ group, although they were not necessarily exposed to OB+ from the 
beginning of pregnancy. We converted birth weight and weight measurements into age- and sex-
adjusted z-scores, based on the WHO 2006 standard [24].  
 
The primary outcome was postnatal weight gain in the first 24 months of life, assessed with 
weight-for-age z scores (WAZ). We also assessed factors associated with birth weight (WAZ at 
birth). 
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Statistical analyses 
Baseline characteristics by birth period were compared with Wilcoxon rank-sum tests for 
continuous variables and Chi-square tests for categorical variables. We used linear regression to 
investigate differences in WAZ at birth, and mixed effects models to examine changes in WAZ 
over time (with a random effect on the infant and fixed effects on the intercept and explanatory 
variables). We used a third order polynomial transformation for age (in months) because weight 
gain is not linear. We tested the effect of covariates on WAZ at birth and during follow-up, and 
we tested for an interaction between the polynomial transformation of age and birth period, with 
a likelihood ratio test. We also did stratified analyses by birth period to identify predictors of 
postnatal weight gain in each birth period. All available weight measurements from enrolment up 
to the last follow-up visit (including infants who were LTFU, transferred out or who died) were 
included in the analysis. All mixed effects models were adjusted for the polynomial 
transformation of age. In multivariable models, we adjusted for infant’s gender, birth weight 
(<2.5kg, ≥2.5kg), type of health facility (health centre, faith-based hospital, district hospital, 
central hospital), and infant antiretroviral exposure during pregnancy or labour (none, or mono- 
or dual-therapy, ART <4 weeks, or ART ≥4 weeks at any stage).  
 
Results from models are presented as differences in WAZ with 95% confidence intervals. All 
analyses were performed in STATA version 14 (Stata Corporation, College Station, Texas, 
USA) and p-values <0.05 were considered significant.  
 
The Malawi National Health Sciences Research Committee and the Cantonal Ethics Committee 
of Bern granted ethical approval. 
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RESULTS 
Of the 16,200 infants enrolled in the HCC programme between February 2010 and May 2015, 
9,355 infants were excluded, of whom 1,318 (14.1%) were born during the pre-OB+ and 8,008 
(85.6%) during the OB+ period. This resulted in a study population of 6,845 HEU infants with a 
median follow-up of 11.3 months (interquartile range (IQR): 5.1-17.0 months). (Figure 1). 
Baseline characteristics of included and excluded infants were significantly different except for 
birth weight and sex (Appendix, Table A1, http://links.lww.com/QAD/B326). 
 
Baseline characteristics by birth period 
A total of 784 (11.5%) HEU infants were born in the pre-OB+ period and 6,061 (88.5%) in the 
OB+ period (Table 1). By the end of follow-up, 33.4% (n=2,285) of HEU infants were LTFU, 
0.4% (n=27) had died, and 1.9% (n=127) had transferred to another facility. More HEU infants 
were LTFU in the pre-OB+ group (48.3%) than in the OB+ group (31.5%); rates of LTFU were 
3.5 per 100 person-months (379/10756) in the pre-OB+ group and 2.7 per 100 person-months 
(1906/70298) in the OB+ group. Infants in the OB+ group were younger at enrolment, more 
likely exposed to ART in-utero (85.1% vs 64.1%) and ART exposure was longer (74.1% vs 
42.2% on ART for ≥4 weeks), than those in the pre-OB+ group. 
 
Factors affecting birth weight 
There were no statistically significant differences in WAZ at birth among infants born before and 
after introduction of OB+ (Table 2). Infants enrolled at a health centre or district hospital had 
significantly higher WAZ at birth than infants enrolled at a central hospital. Exposure to 
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antiretrovirals during pregnancy or labour, irrespective of regimen or duration, had no significant 
effect on WAZ at birth.  
  
If the analysis was stratified by birth period, associations were similar (Appendix, Tables A2a 
and A2b, http://links.lww.com/QAD/B326). In the adjusted analysis the association between type 
of facility and WAZ at birth was however only present in the OB+ group. 
 
Factors affecting postnatal weight gain 
The interaction between polynomial transformation of age and birth period was not significant in 
univariable analysis (p-value 0.287) and was therefore not included in the model. Postnatal WAZ 
was higher in the OB+ group (difference 0.211, 95% CI 0.117-0.306; p<0.0001) irrespective of 
age after adjusting for gender, birth weight, facility type and maternal antiretroviral exposure 
(Table 3 and Figure 2). Other predictors of WAZ over time included a birth weight of ≥2.5kg 
and female gender. Infant’s exposure to antiretrovirals during pregnancy or labour, regardless of 
type of regimen or length of exposure, had no significant impact on postnatal WAZ in the 
univariable analysis. Infants exposed to ART for ≥4 weeks during pregnancy had significantly 
lower WAZ in the first 24 months of life in adjusted analyses. However, when we stratified the 
analysis by birth period (Appendix, Tables 3a and 3b, http://links.lww.com/QAD/B326), only 
infant gender and type of health facility had a significant effect on WAZ in the OB+ period, and 
there was no effect of type and duration of antiretroviral exposure on WAZ in either birth period. 
 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
DISCUSSION 
The proportion of infants exposed to ART during pregnancy or labour increased significantly 
after OB+ was implemented, and infants were exposed to ART for a longer time. WAZ was 
similar at birth among HEU infants born before and after OB+, but postnatal weight gain was 
higher in HEU infants born in the OB+ period than infants born in the pre-OB+ period.   
 
Prolonged exposure to ART, more common in the OB+ period, may increase adverse pregnancy 
outcomes like preterm delivery and low birth weight [25]. The European collaborative study 
found an association between prematurity and ART exposure, for all types of regimens [9]. Some 
studies from resource-limited settings found that lower birth weight was associated with in-utero 
ART exposure [8,26,27] but did not seem to impair postnatal growth [8,27,28].  
 
We found that neither the type of antiretroviral regimen, nor length of in-utero ART exposure 
was associated with WAZ at birth in HEU infants consistent with other African studies 
[12,14,29]. Most infants in our study were exposed to ART in-utero, so a potential negative 
effect of ART was probably counter balanced by the favourable immunological and virological 
response to ART in the pregnant woman, resulting in improved maternal health that benefits 
infants’ outcomes. However, we had no data on CD4 cell counts and viral loads during 
pregnancy. 
 
Disentangling the exact effect of the birth period, the type and length of ART exposure, and the 
CD4 cell count on WAZ at birth and longitudinal weight gain was not possible. Since we 
compared the pre-OB+ period with the OB+ period, the number of drugs and the types of 
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antiretroviral regimens depended on the birth period. During the pre-OB+ period, women who 
were on combination ART had low CD4 cell counts or were in an advanced stage of the disease. 
The association of being on ART ≥4 weeks with slower weight gain may therefore be driven by 
observations in the pre-OB+ period. However, we could not confirm this hypothesis in stratified 
analyses, possibly because of the low sample size. 
Since we did not capture the date of ART initiation, we also do not know if the women had 
started ART pre-conception, in the first trimester, or in the last two trimesters. This is a relevant 
limitation because a study from Brazil showed that birth weight was lower in infants with 
exposure to ART in the first trimester than later exposure or no exposure to ART in-utero [30]. 
Discrepant findings between studies may be related to differences in the populations studied, 
variations in antenatal and postnatal care and contrasting study designs (e.g. adjustment for 
different confounders and different selection criteria).  
 
A number of additional factors were associated with postnatal WAZ. Contrary to other studies 
[31–35], we found no significant differences in WAZ at birth between boys and girls. However, 
girls had higher postnatal WAZ than boys, in agreement with a study done in South Africa  [31]. 
HEU infants with normal weight at birth (≥2.5kg) had higher postnatal WAZ than those with low 
birth weight (<2.5kg) consistent with previous studies [17,36,37]. 
 
We faced several limitations. The first was our inability to determine if OB+ itself spurred 
improvement in postnatal weight gain, or if other factors were responsible. In developing 
countries, poverty, socio-economic conditions, malnutrition, and poor health affect the growth 
and development of children under the age of five [38]. Socio-economic, environmental and 
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immunological factors are also associated with under-nutrition in children born to HIV-infected 
mothers [17,39,40]. We did not adjust for these factors because we had no data. Second, in 
routine clinical care LTFU is often high. Weight measurements are biased by LTFU, because 
children with impaired weight gain are more likely to be LTFU and to die. Therefore, we 
anticipate that weight gain was particularly overestimated in the pre OB+ group. Third, we only 
included large health facilities, so our findings may not be representative of infants from smaller 
rural health centres. Fourth, birth length was not recorded, and height was sporadically recorded 
during follow-up visits, so we could not compare length/height-for-age and weight-for-
length/height z-scores over time. Fifth, we determined birth period according to infant’s date of 
birth. When a clinic implemented OB+, all women attending antenatal care, including those who 
were already on zidovudine prophylaxis, were instructed to switch to triple life-long ART at their 
next visit. In practice, however, the transition to OB+ may have taken some time, and infants 
born soon after the switch to OB+ were not exposed to the policy for the entire period. 
Therefore, inclusion of HEU infants born in the transition period in the OB+ group 
underestimates the positive effect of OB+ on weight gain. Finally, we excluded a large number 
of infants due to missing data whose characteristics were different from those included. 
 
Our study has a number of strengths. We believe we are the first to assess weight gain in routine 
care during the first 24 months of life for HEU infants in the OB+ era. Our study had a large 
sample size, and followed HEU infants over a long period. Our study facilities were 
geographically diverse and included a variety of clinical settings.  
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Our finding of better postnatal weight gain among HEU infants born in the OB+ period is 
encouraging considering the widespread implementation of OB+. To confirm our findings, future 
studies should include small health centres and account for socio-economic characteristics, infant 
feeding practices, and maternal disease progression. OB+ increased exposure to ART during 
pregnancy. The increase did not affect birth weight, and seems to have improved postnatal 
weight gain in HEU infants, possibly because OB+ also improved mothers’ health. 
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Table 1: Characteristics of HIV-exposed, uninfected children by birth period 
 
All infants 
(n = 6,845) 
Child birth period 
Pre Option 
B+ 
(n=784; 
11.5%) 
Option B+ 
(n=6,061; 
88.5%) 
 
 
P-value## 
Age at enrolment (months), 
median (IQR) 2.0 (1.0-3.0) 4.0 (2.0-9.0) 2.0 (1.0-2.0)  < 0.0001
Gender, n (%)   
   Female 3,455 (50.5) 391 (49.9) 3,064 (50.6)  0.720
   Male 3,390 (49.5)        393 
(50.1)
2,997 (49.4)  
PEP at birth, n (%)   
   No 534 (7.8) 136 (17.3) 398 (6.6)  < 0.0001
   Yes 5,999 (87.6) 596 (76.0) 5,403 (89.1)  
   Unknown 312 (4.7) 52 (6.6) 260 (4.3)  
Birth weight, n (%)   
   <2.5kg 823 (12.0) 97 (12.4) 726 (12.0)  0.749
   ≥2.5kg  6,022 (88.0) 687 (87.6) 5,335 (88.0)  
Birth weight (kg), median (IQR) 3.0 (2.7-3.4) 3.0 (2.8-3.4) 3.0 (2.7-3.4)  0.210
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
In-utero antiretroviral exposure, 
n (%)1 
  
   No antiretrovirals 464 (6.8) 109 (13.9) 355 (5.9)  < 0.0001
   Mono- or dual-therapy at any 
stage  
125 (1.8) 125 (15.9) --  
   ART< 4 weeks  at any stage 837 (12.2) 172 (21.9) 665 (11.0)  
   ART ≥ 4 weeks at any stage 4,820 (70.4) 331 (42.2) 4,489 (74.1)  
   Unknown 599 (8.8) 47 (6.0) 552 (9.1)  
Mother’s postpartum status   
   No ART 177 (2.6) 84 (10.7) 93 (1.5)  < 0.0001
   ART 6,276 (91.7) 590 (75.3) 5,686 (93.8)  
   ART with interruptions# 364 (5.3) 102 (13.0) 262 (4.3)  
   Died 9 (0.1) 3 (0.4) 6 (0.1)  
   Unknown 19 (0.3) 5 (0.6) 14 (0.2)  
Follow-up duration (months), 
median (IQR) 
11.3 (5.1-
17.0)
12.0 (6.7-
17.7)
11.2 (4.9-
16.9) 
 
0.004
Outcome at the end of follow-up, 
n (%) 
  
   Lost to follow-up* 2,285 (33.4) 379 (48.3) 1,906 (31.5)  < 0.0001
   Discharged 1,337 (19.5) 362 (46.2) 975 (16.1)  
   Dead 27 (0.4) 6 (0.8) 21 (0.4)  
                                                            
1 ART was defined as a combination of at least three antiretroviral drugs. Before OB+, women eligible for ART 
received a combination of stavudine, lamivudine and nevirapine. Women not eligible for ART received zidovudine 
monotherapy during pregnancy followed by zidovudine + lamivudine dual therapy or single-dose nevirapine during 
labour. During OB+, all women received a combination of tenofovir, lamivudine and efavirenz. 
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   Transferred out 127 (1.9) 13 (1.7) 114 (1.9)  
   Under follow-up 3,069 (44.8) 24 (3.1) 3,045 (50.2)  
Facility type, n (%)   
   Central hospital  637 (9.3) 100 (12.8) 537 (8.9)  < 0.0001
   Health centre 1,003 (14.7) 60 (7.7) 943 (15.6)   
   Faith based hospital 625 (9.1) 105 (13.4) 520 (8.6)  
   District hospital 4,580 (66.9) 519 (66.2) 4,061 (67.0)  
ART: Antiretroviral therapy; PEP: Post exposure prophylaxis (children received zidovudine 
(AZT) in pre-Option B+ and nevirapine (NVP) during Option B+); IQR: Interquartile range.  
# Represents women who missed some ART visits to the health facility  
* Infants who missed a clinic appointment for more than 60 days and did not return to care 
## P values from Wilcoxon rank-sum tests (continuous variables) and Chi-square tests 
(categorical variables).  
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Table 2: Linear regression analysis of weight-for-age z-scores (WAZ) at birth, birth weight; 
n=6,845 
  Univariable  Multivariable  
 β 95% CI P-value* β 95% CI P-value*
Birth period     
   Pre Option B+  0 0.590 0  0.654
   Option B+  
-0.029
-0.133; 
0.075
-0.027 -0.145; 
0.091 
Gender   
   Male  0 0.928 0  0.801
   Female  
0.003
-0.063; 
0.069
-0.009 -0.077; 
0.060 
In-utero antiretroviral 
exposure  
  
   No antiretrovirals  0 0.163 0  0.188
   Mono- or dual-therapy 
at any stage  
 
0.131
-0.142; 
0.404
0.156 -0.133; 
0.444 
   ART <4weeks at any 
stage 
 
-0.090
-0.247; 
0.067
-0.091 -0.248; 
0.066 
   ART ≥4weeks at any 
stage 
 
-0.096
-0.228; 
0.036
-0.093 -0.226; 
0.040 
Facility type   
   Central hospital  0 0.0003 0  0.0002
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
   Health centre  0.259 0.120; 0.398 0.281 0.141; 0.421 
   Faith based hospital  
0.022
-0.132; 
0.176
0.025 -0.132; 
0.182 
   District hospital  0.153 0.037; 0.269 0.138 0.022; 0.255 
ART: Antiretroviral therapy; CI: Confidence interval 
*P values from  likelihood ratio test 
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Table 3: Mixed-effects model of weight-for-age z-scores (WAZ) over time (age: 0-24 months) 
  Univariable*  Multivariable** 
 β 95% CI P-value# β 95% CI P-value#
Birth period     
   Pre Option B+  0 <0.0001 0  <0.0001
   Option B+  
0.180
0. 095; 
0.265
0.211 0.117; 0.306 
Gender   
   Male  0 0.0001 0  <0.0001
   Female  0.108 0.054; 0.162 0.132 0.078; 0.186 
Birth weight   
   <2.5kg  0 <0.0001 0  <0.0001
   ≥2.5kg  
1.093
1. 013; 
1.172
1.108 1.025; 1.191 
In-utero antiretroviral 
exposure  
  
   No antiretrovirals  0 0.851 0  0.042
   Mono- or dual-therapy 
at any stage  
 
0.025
-0.200; 
0.251
0.180 -0.050; 
0.410 
   ART <4 weeks at any 
stage 
 
0.054
-0.078; 
0.185
0.040 -0.085; 
0.165 
   ART ≥4 weeks at any 
stage 
 
-0.018
-0.128; 
0.092
-0.056 -0.162; -
0.050 
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Facility type   
   Central hospital  0 <0.0001 0  <0.0001
   Health centre  
-0.050
-0.163; 
0.064
-0.071 -0.181; 
0.040 
   Faith based hospital  
-0.290
-0.415; -
0.165
-0.290 -0.413; -
0.166 
   District hospital  
-0.098
-0.192; -
0.005
-0.135 -0.226; -
0.044 
ART: Antiretroviral therapy; CI: Confidence interval; p-value from a likelihood ratio test 
* The univariable model assessed the association between WAZ and each variable individually 
with inclusion of the polynomial transformation of age. 
** The multivariable model assessed the association between WAZ and birth period adjusting 
for all independent variables and the polynomial transformation of age.  
# P values from likelihood ratio test 
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Figure 1:
 
 
 Study participants 
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Figure 2: Predicted z-scores from univariable mixed effects model for weight-for-age by birth 
period (i.e. pre Option B+ and Option B+) adjusted for the polynomial transformation of age 
(months). Dotted lines represent 95% confidence intervals 
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